Scarica l'app Stockscreener
1.91
0.26%
0.01
Dopo l'orario di chiusura:
1.93
0.02
+1.05%
Precedente Chiudi:
$1.92
Aprire:
$1.91
Volume 24 ore:
609.08K
Relative Volume:
0.64
Capitalizzazione di mercato:
$270.25M
Reddito:
$15.53M
Utile/perdita netta:
$-52.71M
Rapporto P/E:
-3.801
EPS:
-0.5025
Flusso di cassa netto:
$-59.00M
1 W Prestazione:
+6.35%
1M Prestazione:
+13.24%
6M Prestazione:
+32.76%
1 anno Prestazione:
-6.10%
Intervallo 1D:
$1.90
$2.00
Intervallo di 1 settimana:
$1.79
$2.00
Portata 52W:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Compare PRQR vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.915 | 270.95M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | Oppenheimer | Outperform |
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com India
H.C. Wainwright reiterates ProQR stock rating on platform data - Investing.com
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results - MarketBeat
ProQR: Q2 Earnings Snapshot - 10TV
symbol__ Stock Quote Price and Forecast - CNN
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks
ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ProQR Therapeutics NV (PRQR) Stock News Today - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – MUN:0PQ - TradingView
ProQR Therapeutics (PRQR) CEO de Boer Daniel Anton Buys 200,000 Shares, Signaling Confidence - GuruFocus
PRQR|ProQR Therapeutics NV|Price:1.860|Chg%:+0.030 - TradingKey
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) CEO boosts stake with 200,000-share buy - Stock Titan
ProQR Therapeutics N.V. Revenue Breakdown – NASDAQ:PRQR - TradingView
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aberdeen Group (PRQR) discloses 6.33% ProQR Therapeutics stake via abrdn Inc. - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Buys 150,000 Shares - MarketBeat
ProQR Therapeutics N.V. Revenue Breakdown – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.060 - TradingKey
PRQR|ProQR Therapeutics NV|Price:1.730|Chg%:+0.010 - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProQR Therapeutics NV (PRQR) Institutional Confidence - TradingKey
ProQR Therapeutics NV (PRQR) Balance Sheet - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics N.V. Revenue Breakdown – BMV:PRQR/N - TradingView
TradingKey - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eli Lilly (NYSE: LLY) reports 21.99M-share beneficial stake in ProQR Therapeutics - Stock Titan
Privium Fund Management B.V. Increases Stake in ProQR Therapeuti - GuruFocus
Bart Filius Acquires Additional Shares in ProQR Therapeutics NV - GuruFocus
Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com South Africa
Proqr Therapeutics N.v. Insider Bought Shares Worth $257,925, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) director purchases 150,000 Ordinary Shares - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR Therapeutics (PRQR) Gains 1.8% as Shares Test Key Resistance Near $1.78Entry Point Alerts - dars.gov.et
PRQR Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Pipeline DevelopmentSlow Growth Warning - dars.gov.et
ProQR Therapeutics N.V. SEC Filing (Jul 16, 2026) - Stock Titan
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet - Stock Titan
Aescap group and Patrick Krol report ProQR (PRQR) shareholdings - Stock Titan
Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares - MarketBeat
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Proqr Therapeutics N V Azioni (PRQR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Filius Bart | Director |
Jul 17 '26 |
Buy |
1.72 |
150,000 |
257,925 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 09 '26 |
Buy |
1.74 |
150,000 |
261,000 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 07 '26 |
Buy |
1.59 |
150,000 |
238,500 |
150,000 |
| Filius Bart | Director |
Jun 26 '26 |
Buy |
1.54 |
150,000 |
231,000 |
150,000 |
2.67%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):